| Health / Medical Topics |
HPV 16 L1-VLP
A vaccine consisting of human papillomavirus-derived noninfectious virus-like particles (VLPs), containing the L1 major capsid protein. Vaccination with HPV 16 L1-VLP results in increases in T cell-proliferative response to HPV 16 L1-VLP, as well as significant increases in cytokine (interferon-gamma, interleukin-5 and -10) responses to L1 VLP. This agent may reduce the incidence of persistent HPV-16 infection, which may be responsible for half of all cases of cervical cancer including high-grade cervical intraepithelial neoplasia. (NCI Thesaurus)
YOU MAY ALSO LIKE
A synthetic peptide vaccine consisting of amino acids 86 through 93 (TLGIVCPI) of the viral oncoprotein human papillomavirus (HPV) 16 E7. Vaccination…
A peptide based vaccine consisting of amino acids 12 through 20 of the E7 gene of the Human Papilloma Virus type…
A peptide derived from the oncogenic human papillomavirus (HPV) early gene product E6. The HPV 16 transforming protein E6 is expressed…
A type of virus that can cause abnormal tissue growth (for example, warts) and other changes to cells. Infection for a long…
Human HPSE2 wild-type allele is located within 10q23-q24 and is approximately 777 kb in length. This allele, which encodes heparanase-2 protein, plays…
This gene is involved in extracellular matrix remodeling.
